
EquitySector - HealthcareVery High Risk
Regular
NAV (14-Oct-26)
Returns (Since Inception)
Fund Size
₹1,430 Cr
Expense Ratio
2.20%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.63%
+11.12% (Cat Avg.)
3 Years
+20.20%
+19.56% (Cat Avg.)
5 Years
+13.29%
+13.08% (Cat Avg.)
10 Years
+13.15%
+14.13% (Cat Avg.)
Since Inception
+14.72%
— (Cat Avg.)
| Equity | ₹1,345.83 Cr | 94.12% |
| Others | ₹84.02 Cr | 5.88% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹109 Cr | 7.62% |
| Divi's Laboratories Ltd | Equity | ₹88 Cr | 6.15% |
| Net Current Assets | Cash | ₹83.72 Cr | 5.85% |
| Dr Reddy's Laboratories Ltd | Equity | ₹74.86 Cr | 5.24% |
| Ajanta Pharma Ltd | Equity | ₹68.8 Cr | 4.81% |
| Gland Pharma Ltd | Equity | ₹57.99 Cr | 4.06% |
| Alkem Laboratories Ltd | Equity | ₹52.93 Cr | 3.70% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹43.28 Cr | 3.03% |
| Caplin Point Laboratories Ltd | Equity | ₹43.2 Cr | 3.02% |
| Global Health Ltd | Equity | ₹42.32 Cr | 2.96% |
| Lupin Ltd | Equity | ₹41.38 Cr | 2.89% |
| Ipca Laboratories Ltd | Equity | ₹40.23 Cr | 2.81% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹39.98 Cr | 2.80% |
| Cohance Lifesciences Ltd | Equity | ₹39.96 Cr | 2.79% |
| Marksans Pharma Ltd | Equity | ₹32.23 Cr | 2.25% |
| Rainbow Childrens Medicare Ltd | Equity | ₹31.54 Cr | 2.21% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹30.25 Cr | 2.12% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹29.84 Cr | 2.09% |
| Aurobindo Pharma Ltd | Equity | ₹29.57 Cr | 2.07% |
| Fortis Healthcare Ltd | Equity | ₹28.88 Cr | 2.02% |
| Procter & Gamble Health Ltd | Equity | ₹27.82 Cr | 1.95% |
| Anthem Biosciences Ltd | Equity | ₹25.76 Cr | 1.80% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹25.1 Cr | 1.76% |
| Dr. Lal PathLabs Ltd | Equity | ₹23.88 Cr | 1.67% |
| Biocon Ltd | Equity | ₹23.14 Cr | 1.62% |
| Metropolis Healthcare Ltd | Equity | ₹20.96 Cr | 1.47% |
| Windlas Biotech Ltd | Equity | ₹20.29 Cr | 1.42% |
| Cipla Ltd | Equity | ₹20.19 Cr | 1.41% |
| Blue Jet Healthcare Ltd | Equity | ₹20.18 Cr | 1.41% |
| Alembic Pharmaceuticals Ltd | Equity | ₹20.04 Cr | 1.40% |
| Viyash Scientific Ltd | Equity | ₹19.85 Cr | 1.39% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹19.02 Cr | 1.33% |
| Sudeep Pharma Ltd | Equity | ₹18.33 Cr | 1.28% |
| Sai Life Sciences Ltd | Equity | ₹18.01 Cr | 1.26% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹16.09 Cr | 1.13% |
| Laxmi Dental Ltd | Equity | ₹15.38 Cr | 1.08% |
| Manipal Health Enterprises Ltd | Equity | ₹15.05 Cr | 1.05% |
| Aarti Pharmalabs Ltd | Equity | ₹14.31 Cr | 1.00% |
| Pfizer Ltd | Equity | ₹13.3 Cr | 0.93% |
| Orchid Pharma Ltd | Equity | ₹10.11 Cr | 0.71% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹9.61 Cr | 0.67% |
| Jubilant Pharmova Ltd | Equity | ₹9.23 Cr | 0.65% |
| Indegene Ltd | Equity | ₹7.1 Cr | 0.50% |
| Syngene International Ltd | Equity | ₹5.96 Cr | 0.42% |
| Emcure Pharmaceuticals Ltd | Equity | ₹2.91 Cr | 0.20% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.3 Cr | 0.02% |
Large Cap Stocks
18.22%
Mid Cap Stocks
33.63%
Small Cap Stocks
41.23%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,345.83 Cr | 94.12% |
Standard Deviation
This fund
16.19%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.91
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.20% | Exit Load 1.00% | Fund Size ₹1,430 Cr | Age 27 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,71,805 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments